PL376473A1 - Treatment of diabetes - Google Patents

Treatment of diabetes

Info

Publication number
PL376473A1
PL376473A1 PL03376473A PL37647303A PL376473A1 PL 376473 A1 PL376473 A1 PL 376473A1 PL 03376473 A PL03376473 A PL 03376473A PL 37647303 A PL37647303 A PL 37647303A PL 376473 A1 PL376473 A1 PL 376473A1
Authority
PL
Poland
Prior art keywords
methods
diabetes
treatment
gastin
complement
Prior art date
Application number
PL03376473A
Other languages
English (en)
Polish (pl)
Inventor
Stephen J. Brand
Antonio Cruz
Aleksandra Pastrak
Yin Hew
Original Assignee
Waratah Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Waratah Pharmaceuticals, Inc. filed Critical Waratah Pharmaceuticals, Inc.
Publication of PL376473A1 publication Critical patent/PL376473A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A61L27/3695—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the function or physical properties of the final product, where no specific conditions are defined to achieve this
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/595—Gastrins; Cholecystokinins [CCK]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Cell Biology (AREA)
  • Botany (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
PL03376473A 2002-10-22 2003-10-22 Treatment of diabetes PL376473A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US42039902P 2002-10-22 2002-10-22
US42018702P 2002-10-22 2002-10-22
US42810002P 2002-11-21 2002-11-21
US42856202P 2002-11-22 2002-11-22

Publications (1)

Publication Number Publication Date
PL376473A1 true PL376473A1 (en) 2005-12-27

Family

ID=32180693

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03376473A PL376473A1 (en) 2002-10-22 2003-10-22 Treatment of diabetes

Country Status (15)

Country Link
US (3) US20060189520A1 (OSRAM)
EP (2) EP2080521A1 (OSRAM)
JP (1) JP2006506386A (OSRAM)
KR (1) KR20050074492A (OSRAM)
AT (1) ATE421333T1 (OSRAM)
AU (1) AU2003283004A1 (OSRAM)
BR (1) BR0315523A (OSRAM)
CA (1) CA2501677A1 (OSRAM)
DE (1) DE60326002D1 (OSRAM)
DK (1) DK1569680T3 (OSRAM)
ES (1) ES2320754T3 (OSRAM)
MX (1) MXPA05004202A (OSRAM)
NO (1) NO20052419L (OSRAM)
PL (1) PL376473A1 (OSRAM)
WO (1) WO2004037195A2 (OSRAM)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6558952B1 (en) * 1992-12-14 2003-05-06 Waratah Pharmaceuticals, Inc. Treatment for diabetes
GB9409496D0 (en) * 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
EP1351742B1 (en) 2001-01-12 2008-10-15 Waratah Pharmaceuticals Inc. Compositions for inducing islet neogenesis, containing gastrin/cck receptor ligands and egf receptor ligands
US7037504B2 (en) * 2001-10-23 2006-05-02 Waratah Pharmaceuticals, Inc. Epidermal growth factor protein and gene, and methods of use therefor
IL165242A0 (en) * 2002-05-24 2005-12-18 Waratah Pharmaceuticals Inc Treatment for diabetes
ES2334268T3 (es) 2002-06-07 2010-03-08 Waratah Pharmaceuticals, Inc. Procedimientos y composiciones para el tratamiento de la diabetes.
EP1837031B1 (en) 2002-06-07 2009-10-14 Waratah Pharmaceuticals, Inc. Compositions and methods for treating diabetes
US20040229810A1 (en) * 2002-10-22 2004-11-18 Antonio Cruz Gastrin compositions and formulations, and methods of use and preparation
PL376473A1 (en) * 2002-10-22 2005-12-27 Waratah Pharmaceuticals, Inc. Treatment of diabetes
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
CA2523267C (en) 2003-04-23 2013-09-03 Biovalve Technologies, Inc. Hydraulically actuated pump for long duration medicament administration
JP2007513059A (ja) * 2003-05-27 2007-05-24 ワラタ ファーマシューティカルズ， インコーポレイテッド ガストリン化合物を含む組成物および糖尿病におけるそれらの使用
US20080039379A1 (en) * 2003-05-27 2008-02-14 Waratah Pharmaceuticals, Inc. Compositions Comprising Gastrin Compounds and Their Use in Diabetes
US8636721B2 (en) 2003-11-20 2014-01-28 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Portable hand pump for evacuation of fluids
AU2005207870B2 (en) * 2004-01-30 2010-08-19 Waratah Pharmaceuticals, Inc. The combined use of GLP-1 agonists and gastrin for regulating blood glucose levels
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
WO2006000567A2 (en) * 2004-06-28 2006-01-05 Novo Nordisk A/S Use of glp-1 receptor agonists and / or dpp-iv inhibitors in combination with proton pump inhibitors and ppar agonists for the preparation of a medicament for the treatment of diabetes type i i and impaired pancreatic beta-cell function
US20090117102A1 (en) * 2004-07-01 2009-05-07 Antonio Cruz Methods and compositions using CD3 agonists
US9089636B2 (en) 2004-07-02 2015-07-28 Valeritas, Inc. Methods and devices for delivering GLP-1 and uses thereof
US8361976B2 (en) 2004-07-09 2013-01-29 University Of Massachusetts Therapeutic alteration of transplantable tissues through in situ or ex vivo exposure to RNA interference molecules
US8337475B2 (en) 2004-10-12 2012-12-25 C. R. Bard, Inc. Corporeal drainage system
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
EP2390264A1 (en) 2005-02-11 2011-11-30 Amylin Pharmaceuticals Inc. GIP analog and hybrid polypeptides with selectable propperties
WO2007019522A2 (en) * 2005-08-04 2007-02-15 Carlos Lopez Reversal of adult onset disorders with granulocyte-colony stimulating factors
US8177772B2 (en) 2005-09-26 2012-05-15 C. R. Bard, Inc. Catheter connection systems
WO2007041833A1 (en) * 2005-10-07 2007-04-19 Waratah Pharmaceuticals, Inc. Combined use of dpp iv inhibitors and gastrin compounds
US20070100322A1 (en) * 2005-10-31 2007-05-03 Ramakrishna Venugopalan Method of removing a stylette from a catheter
WO2007064757A1 (en) * 2005-11-29 2007-06-07 University Of Florida Research Foundation, Inc. Anti-thymocyte globulin to prevent or delay the onset or the progression on type 1 diabetes
WO2007095737A1 (en) * 2006-02-21 2007-08-30 Waratah Pharmaceuticals Inc. Combination therapy for the treatment of diabetes comprising an exendin agonist and a gastrin compound
JP2009527504A (ja) * 2006-02-23 2009-07-30 イオメディックス スリープ インターナショナル エスアールエル 良質な睡眠の誘導および維持のための組成物および方法
EP2005309B1 (en) 2006-03-30 2016-02-17 Valeritas, Inc. Multi-cartridge fluid delivery device
ATE481963T1 (de) 2006-05-30 2010-10-15 Intarcia Therapeutics Inc Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
AU2007284759B2 (en) 2006-08-09 2010-10-28 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
MX2009011123A (es) 2007-04-23 2009-11-02 Intarcia Therapeutics Inc Formulaciones de suspensiones de peptidos insulinotropicos y sus usos.
WO2009023566A2 (en) 2007-08-09 2009-02-19 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
WO2009046015A2 (en) * 2007-09-30 2009-04-09 University Of Florida Research Foundation, Inc. Combination therapies for treating type 1 diabetes
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
DE102008023820A1 (de) * 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
US8697098B2 (en) 2011-02-25 2014-04-15 South Dakota State University Polymer conjugated protein micelles
US8512737B1 (en) * 2008-06-03 2013-08-20 Abbott Cardiovascular Systems Inc. Embolic delivery of therapeutic agents
EA020091B1 (ru) 2008-08-07 2014-08-29 Ипсен Фарма С.А.С. Аналоги глюкозозависимого инсулинотропного полипептида (gip), модифицированные по n-концу
KR20110043688A (ko) 2008-08-07 2011-04-27 입센 파마 에스.에이.에스 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드 유사체
US20100092566A1 (en) * 2008-10-15 2010-04-15 Alessi Thomas R Highly concentrated drug particles, formulations, suspensions and uses thereof
US8821872B2 (en) * 2009-05-01 2014-09-02 Jill P. Smith Identification and characterization of a specific CCK-C receptor antibody for human pancreatic cancer and its use for early detection and staging of pancreatic cancer
US8383671B1 (en) 2009-06-18 2013-02-26 Abbott Cardiovascular Systems Inc. Method of treating malignant solid tumors
KR102093612B1 (ko) 2009-09-28 2020-03-26 인타르시아 세라퓨틱스 인코포레이티드 실질 항정상태 약물 전달의 신속 확립 및/또는 종결
BR112012016666A2 (pt) * 2010-01-05 2018-06-05 Beacon Endoscopic Corp métodos e aparelhos para anastomose de compressão induzida por imã entre órgãos adjacentes.
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
MX359070B (es) 2010-12-01 2018-09-13 Alderbio Holdings Llc Composiciones anti-ngf y uso de las mismas.
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CA2828253C (en) 2011-02-25 2016-10-18 South Dakota State University Polymer conjugated protein micelles
AU2012289921B2 (en) * 2011-08-03 2017-05-04 Revivallon Biopharmaceutical Co., Ltd Treatment of type 2 diabetes with FTY720
GB201304038D0 (en) * 2013-03-06 2013-04-17 Nhs Blood & Transplant Treated cells and therapeutic uses
BR102013017626A2 (pt) * 2013-06-14 2015-02-10 Univ Rio De Janeiro Bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, uso de bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, composições farmacêuticas de baixa toxicidade, adjuvante para a prevenção ou tratamento das doenças, medicamento, método de tratamento ou prevenção de doenças.
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
KR102650751B1 (ko) 2015-06-03 2024-03-22 인타르시아 세라퓨틱스 인코포레이티드 임플란트 배치 및 제거 시스템들
WO2017136745A1 (en) * 2016-02-05 2017-08-10 Entrega Inc. Oral dosage form with drying agent for delivery of active agent
CA3024479A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
MX2019008006A (es) 2017-01-03 2019-08-29 Intarcia Therapeutics Inc Metodos que comprenden la administracion continua de un agonista del receptor de glp-1 y la co-administracion de un farmaco.
US20220211770A1 (en) * 2019-05-01 2022-07-07 Sernova Corporation Methods of treating diabetes using devices for cellular transplantation
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
CN113106054B (zh) * 2020-01-13 2022-10-14 青岛瑞思德生物科技有限公司 一种将间充质干细胞诱导分化为胰岛细胞的诱导剂
CN111394311B (zh) * 2020-04-20 2022-07-01 青岛瑞思德生物科技有限公司 一种诱导间充质干细胞向角膜上皮细胞分化的无血清完全培养基
MX2022015872A (es) 2020-06-11 2023-05-16 Provention Bio Inc Metodos y composiciones para prevenir diabetes tipo 1.

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3451974A (en) * 1965-12-01 1969-06-24 Du Pont Process for moisture conditioning of nylon
US3487139A (en) * 1967-05-25 1969-12-30 Mojonnier Inc Albert Method of forming plastic articles
US4289817A (en) * 1970-09-14 1981-09-15 Valyi Emery I Decorated multilayered hollow plastic container
US4421712A (en) * 1980-08-13 1983-12-20 Maryland Cup Corporation Continuously rotary thermo-forming systems and apparatus of the pressure assist, plug assist and match mold type
US4393373A (en) 1981-03-16 1983-07-12 Fuji Electrochemical Co., Ltd. Piezoelectric audible sound generator
JPS6028994A (ja) * 1983-07-08 1985-02-14 Wakunaga Seiyaku Kk 〔２１―ロイシン〕ヒトウロガストロン
US4686283A (en) 1985-04-16 1987-08-11 Syntex (U.S.A.) Inc. Analogs of transforming and epidermal growth factor fragments for therapy and diagnosis
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US5120712A (en) * 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5554386A (en) 1986-07-03 1996-09-10 Advanced Magnetics, Inc. Delivery of therapeutic agents to receptors using polysaccharides
JPH04503154A (ja) 1988-11-07 1992-06-11 ルニベルシー・ド・ルタ・ア・リージュ 変型ヒト成長ホルモン
ES2063912T3 (es) * 1989-01-24 1995-01-16 Aphton Corp Composiciones inmunogenicas frente a peptidos de gastrina.
US4997950A (en) * 1989-04-20 1991-03-05 Richard Finbar Murphy Novel C-terminal gastrin antagonists
US5158935A (en) * 1989-05-12 1992-10-27 Chiron Corporation Human epidermal growth factor having substitution at position 11
US5128242A (en) 1989-06-19 1992-07-07 The Administrators Of The Tulane Educational Fund Hypothalamic polypeptides with adenylate cyclase stimulating activity
US5198542A (en) 1989-06-20 1993-03-30 Takeda Chemical Industries, Inc. Dna encoding a pitvitary adenylate cyclase activating protein and use thereof
US5362716A (en) * 1989-12-27 1994-11-08 The United States Of America As Represented By The Department Of Health And Human Services Methods for stimulating hematopoietic progenitors using hepatocyte growth factor and lymphokines
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
EP0768090A3 (en) 1990-07-18 1997-06-18 Takeda Chemical Industries Ltd Polypeptides with c-AMP producing activity for the prevention of neuronal cell death
EP0586549B1 (en) 1991-05-10 2000-09-20 Genentech, Inc. Selecting ligand agonists and antagonists
WO1993003757A1 (en) 1991-08-16 1993-03-04 Chiron Corporation Muteins of epidermal growth factor exhibiting enhanced binding at low ph
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
BR9306895A (pt) * 1992-08-11 1998-12-08 Khashoggi E Ind Artigo de manufatura recipiente para o armazenamento distribuição acondicionamento ou parcelamento de produtos alimentícios ou bebidas processo para manufaturar esse recipiente e produto manufaturado
US5885956A (en) * 1992-12-14 1999-03-23 Research Triangle Pharmaceuticals Treatment for diabetes using a gastrin/CCK receptor ligand and an EGF receptor ligand
US6558952B1 (en) * 1992-12-14 2003-05-06 Waratah Pharmaceuticals, Inc. Treatment for diabetes
US6284727B1 (en) * 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
CA2121192A1 (en) 1993-04-21 1994-10-22 Kiminori Atsumi Collagen membranes
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5773569A (en) 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US6001647A (en) * 1994-04-28 1999-12-14 Ixion Biotechnology, Inc. In vitro growth of functional islets of Langerhans and in vivo uses thereof
WO1995029690A1 (en) * 1994-04-29 1995-11-09 The Trustees Of The University Of Pennsylvania Biologically active peptides and methods of identifying the same
US5587309A (en) * 1994-04-29 1996-12-24 The United States Of America As Represented By The Department Of Health And Human Services Method of stimulating proliferation and differentiation of human fetal pancreatic cells ex vivo
GB9409496D0 (en) * 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US5885574A (en) 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US5993850A (en) * 1994-09-13 1999-11-30 Skyepharma Inc. Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US20010006943A1 (en) * 1994-12-23 2001-07-05 Ejvind Jensen Protracted GLP-1 compositions
US6458764B1 (en) * 1995-05-26 2002-10-01 Theratechnologies Inc. GRF analogs with increased biological potency
AU6163196A (en) 1995-06-07 1996-12-30 Smithkline Beecham Corporation Method for obtaining receptor agonist antibodies
US5766620A (en) * 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
US6346390B1 (en) 1996-03-08 2002-02-12 Receptron, Inc. Receptor derived peptides involved in modulation of response to ligand binding
EP0966297B2 (en) * 1996-08-08 2013-02-27 Amylin Pharmaceuticals, Inc. Regulation of gastrointestinal motility
US6458924B2 (en) * 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US6011155A (en) * 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
WO1998030231A1 (en) * 1997-01-07 1998-07-16 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the reduction of food intake
EP1032388A4 (en) 1997-10-31 2002-10-02 Smithkline Beecham Corp NEW METAL COMPLEXES
FR2770843B1 (fr) 1997-11-13 2000-01-14 Lavipharm Lab Association prolamines-lipides polaires vegetaux, son procede de preparation et ses applications
WO1999029336A1 (en) * 1997-12-05 1999-06-17 Eli Lilly And Company Glp-1 formulations
JP2003522099A (ja) * 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
US20020127254A1 (en) 1998-06-25 2002-09-12 Lavipharm Laboratories Inc. Devices for local and systemic delivery of active substance and methods of manufacturing thereof
US6242563B1 (en) 1998-07-20 2001-06-05 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Peptide analogues
AU5027299A (en) * 1998-07-31 2000-02-28 Novo Nordisk A/S Use of glp-1 and analogues for preventing type ii diabetes
WO2000029438A1 (en) 1998-11-19 2000-05-25 Millennium Pharmaceuticals, Inc. Egf-like nucleic acids and polypeptides and uses thereof
ATE460942T1 (de) * 1999-01-14 2010-04-15 Amylin Pharmaceuticals Inc Exendine zur glucagon suppression
DK1140145T4 (da) * 1999-01-14 2019-07-22 Amylin Pharmaceuticals Llc Hidtil ukendte exendinagonistformuleringer og fremgangsmåder til indgivelse deraf
US6451974B1 (en) * 1999-03-17 2002-09-17 Novo Nordisk A/S Method of acylating peptides and novel acylating agents
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US6506724B1 (en) * 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
CA2392615A1 (en) * 1999-12-06 2001-06-07 The General Hospital Corporation Pancreatic stem cells and their use in transplantation
JP2003523199A (ja) * 2000-02-18 2003-08-05 ザ ウォルター アンド イライザ ホール インスティチュート オブ メディカル リサーチ 膵島細胞成長因子
ES2582376T3 (es) * 2000-03-31 2016-09-12 Royalty Pharma Collection Trust Método para la mejora de la señalización de islotes en diabetes mellitus y para su prevención
EP1351742B1 (en) * 2001-01-12 2008-10-15 Waratah Pharmaceuticals Inc. Compositions for inducing islet neogenesis, containing gastrin/cck receptor ligands and egf receptor ligands
EP1385935A4 (en) * 2001-03-29 2004-09-15 Ixion Biotechnology Inc METHOD FOR TRANSDIFFERENTIATION OF NON-PANCREATIC STEM CELLS IN THE PANCREAS DIFFERENTIATION PATHWAY
CA2451838A1 (en) * 2001-05-25 2002-12-05 Cythera, Inc. Stem cell differentiation
DK1412384T3 (da) * 2001-06-28 2008-04-28 Novo Nordisk As Stabil formulering af modificeret GLP-1
US7037504B2 (en) * 2001-10-23 2006-05-02 Waratah Pharmaceuticals, Inc. Epidermal growth factor protein and gene, and methods of use therefor
KR101008868B1 (ko) * 2001-12-07 2011-01-17 제론 코포레이션 인간 배아 줄기세포 유래의 섬세포
PL376473A1 (en) * 2002-10-22 2005-12-27 Waratah Pharmaceuticals, Inc. Treatment of diabetes

Also Published As

Publication number Publication date
MXPA05004202A (es) 2005-09-20
EP1569680A2 (en) 2005-09-07
WO2004037195A2 (en) 2004-05-06
EP2080521A1 (en) 2009-07-22
WO2004037195A3 (en) 2005-06-16
DK1569680T3 (da) 2009-05-18
EP1569680B1 (en) 2009-01-21
DE60326002D1 (de) 2009-03-12
US20060189520A1 (en) 2006-08-24
JP2006506386A (ja) 2006-02-23
KR20050074492A (ko) 2005-07-18
AU2003283004A1 (en) 2004-05-13
NO20052419D0 (no) 2005-05-19
US20090036381A1 (en) 2009-02-05
US20040209801A1 (en) 2004-10-21
BR0315523A (pt) 2005-08-30
EP1569680A4 (en) 2006-05-17
NO20052419L (no) 2005-07-07
CA2501677A1 (en) 2004-05-06
ATE421333T1 (de) 2009-02-15
ES2320754T3 (es) 2009-05-28

Similar Documents

Publication Publication Date Title
EP1569680A4 (en) TREATMENT OF DIABETES.
IL165285A0 (en) Compositions and methods for treating diabetes
AU2003245282A1 (en) Stent coatings with sustained drug release rate
MXPA03007837A (es) Composiciones para suministrar bisfosfonatos.
CY1119865T1 (el) Φαρμακευτικες συνθεσεις για την αντιμετωπιση της νοσου του παρκινσον
ATE420632T1 (de) Titrationsdosierschema für kontrolliert freigesetztes tramadol
IL183982A0 (en) Controlled release formulation for oral administration for treating diabetes containing metformin and methods for the preparation thereof
NO20065368L (no) Terapeutiske blandinger inneholdende minst et pyrrolobenzodiazepinderivat og fludarabin
BR0314356A (pt) Formulações de liberação retardada para administração oral de um agente terapêutico polipetìdeo e métodos utilizando as mesmas
LU91989I9 (OSRAM)
DE602005018178D1 (de) Phospholipid und verunreinigungsbeständige beschichtungszusammensetzungen
IL156828A0 (en) Prolonged efficacy of islet neogenesis therapy methods with a gastrin/cck receptor ligand and an egf receptor ligand composition in subjects with preexisting diabetes
DE60331236D1 (de) Orale zusammensetzungen zur behandlung von diabetes
MX2010006204A (es) Derivados de oxindol 5,6-disubstituidos y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
MX363023B (es) Formulaciones orales de analogos de citidina y metodos para usar los mismos.
MX2007004862A (es) Nuevos derivados de sulfonamida como moduladores del receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias.
AR052774A1 (es) Inmunoterapia para trastornos autoinmunes
DK0589893T3 (da) Anvendelse af et bakteriocin som antimikrobielt middel til fremstilling af et lægemiddel til behandl ing af maveforstyrrelser forbundet med helicobacter pylori
SG152237A1 (en) Pharmaceutical combinations containing benzoxazine for treating respiratory diseases
HRP20080569T3 (en) Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin
NO20091691L (no) Pegylert PTH som PTH-reseptormodulatorer og anvendelse derav
ATE554753T1 (de) 2,2'-dithio-bis(ethansulfonat) für den einsatz zur hemmung paclitaxel-induzierter abnormer thermoesthesia
AR025060A1 (es) Formulaciones farmaceuticas en capsulas de hidroxipropilmetilcelulosa
MX2007004861A (es) Derivados de sulfonamida novedosos como moduladores de receptor glucocorticoide para el tratamiento de enfermedades inflamatorias.
MXPA05011788A (es) Compuestos quimicos.

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)